Immutep (ASX:IMM) said its Phase II EFTISARC-NEO trial evaluating the therapy of the company's drug candidate eftilagimod alfa, in combination with prescription medicine Keytruda and radiotherapy as treatment for patients with resectable soft tissue sarcoma (STS), showed an increase in tumor fibrosis rate, according to a Monday filing with the Australian bourse.
The trial showed that the combination therapy exceeded the median tumor fibrosis rate of 35% compared to the historical median of 15% observed with radiotherapy alone, meeting the trial's primary endpoint, the filing said.
Tumor fibrosis is linked to improved overall and recurrence-free survival in patients with STS.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。